Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Glen Weiss, Greg Hannon, Jonathan Eisen, More

Glen Weiss

Glen Weiss has been appointed chief medical officer of Circulogene. Prior to his appointment, he was director of clinical research and trials at the Cancer Treatment Centers of America. He holds a medical degree from the Sackler School of Medicine in Tel Aviv and an MBA from the W.P. Carey School of Business at Arizona State University.


Greg Hannon

Cancer Research UK and the University of Cambridge recently announced Greg Hannon as the new director of the Cancer Research UK Cambridge Institute. Hannon joined the Cancer Research UK Cambridge Institute in 2014 as a senior group leader. Prior to that he spent more than 20 years at Cold Spring Harbor Laboratory where he was a Howard Hughes Medical Institute Investigator and chaired the cancer genetics program as part of the Lab's National Cancer Institute-designated cancer center.


Jonathan Eisen

Zymo Research recently appointed Jonathan Eisen to its scientific advisory board. Eisen currently works at the University of California, Davis, where he holds appointments in the Department of Evolution and Ecology in the College of Biological Sciences and in the Department of Medical Microbiology and Immunology in the School of Medicine. He received his PhD in biology in 1998 from Stanford University, where he worked on the evolution of DNA repair. He has published more than 300 scientific articles and is a member of the American Academy of Microbiology.


For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.